Published on : Sep 26, 2016
ALBANY, New York, September 26, 2016: ResearchMoz.us has recently announced the addition of a new market research report to its comprehensive collection of research studies. The 202-page research report, titled “Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way,” provides an inclusive overview, focusing on the existing commercial and clinical landscape and the current treatment procedures in the global market. Additionally, a comprehensive study of innovative advancements for disease diagnosis, pathogenesis, prognosis, have also been discussed at length in the report.
The global market for respiratory drugs is expected to witness significant growth in the coming years, owing to the growing emphasis on novel and targeted therapies. The past performance and projections of the market have been included in the research report to offer a clear understanding and help key players in formulating effective business strategies.
The growing prevalence of respiratory disorders, growing geriatric population, and tremendous rise in environmental pollution are some of the primary factors fuelling the growth of the global respiratory drugs market. In addition, the promising late-stage pipeline molecules and increased use of tobacco are projected to boost the demand for respiratory drugs in the next few years. The introduction of patient assistance programs and the growing awareness regarding respiratory diseases are expected to contribute extensively towards the development of the market.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=811827
On the other hand, the rising patient preference for complementary and alternative medicine (CAM), multiple patent expirations, and unknown etiology of idiopathic pulmonary fibrosis (IPF) and asthma are some of the key factors restricting the growth of the respiratory drugs market across the globe. Moreover, the adverse effects of drugs and low diagnosis rates are estimated to curb the growth of the overall market in the next few years. Nonetheless, use of biologics and strategic alliances are expected to generate potential opportunities for the prominent players in the market.
As per the research study, the asthma segment is expected to hold a massive share of the global respiratory drugs market throughout the forecast period. The growing prevalence of asthma and rising popularity of LABA/ICS combination drugs are expected to fuel the growth of this segment. Some of the other key disease-based segments studies in the research report are COPD, allergic rhinitis, idiopathic pulmonary fibrosis, pulmonary hypertension, and cystic fibrosis.
Furthermore, the research study throws light on the competitive landscape of the global respiratory drugs market. Some of the leading players included in the research study are Novartis, Boehringer Ingelheim, GlaxoSmithKline, Roche, AstraZeneca, and Vertex. The vendor analysis presented in the research study helps in determining how much dependent the leading players are on the revenue generated from diverse respiratory disorder products. Additionally, the study highlights the key strategies adopted by these players to sustain in the market and establish their presence across the globe.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]